创新药高质量发展迎重磅利好，高弹性、同类费率最低的科创医药ETF(588860) 有望受益

Group 1 - The core viewpoint of the articles is the support for the development of innovative drugs in China, as outlined in the measures released by the National Healthcare Security Administration and the National Health Commission, which include 16 specific initiatives to enhance the entire chain of innovative drug research and development, access, hospital use, and multi-payment systems [1] - The innovative drug sector has shown strong performance, with the Sci-Tech Innovation Pharmaceutical ETF (588860) achieving a trading volume of 33.04 million yuan on average over the past six months, ranking first among comparable funds [1] - The Sci-Tech Innovation Pharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which consists of 50 large-cap companies in the biopharmaceutical and related sectors, reflecting the overall performance of representative companies in the innovative pharmaceutical industry [1] Group 2 - The Sci-Tech Innovation Pharmaceutical ETF (588860) is characterized by high elasticity, with potential index fluctuations of up to 20%, focusing on medical innovation devices and innovative drugs, and has the lowest management and custody fees among similar ETFs at 0.45% and 0.07% respectively [2] - Domestic innovative drug companies are entering a harvest phase after years of R&D investment, with recent favorable policies and increasing overseas licensing amounts contributing to performance growth [2] - The market outlook remains positive for innovative drug companies with true innovation capabilities, as they are expected to have greater valuation elasticity, while cyclical recovery presents opportunities in upstream sectors like CXO and scientific services [2] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (ICBC, 159217) closely tracks the National Index of Hong Kong Stock Connect Innovative Drugs, with a management fee of 0.40% and a custody fee of 0.07%, both among the lowest in its category [3] - The tracking error of the Hong Kong Stock Connect Innovative Drug ETF over the past two months is 0.8395%, indicating a strong alignment with its benchmark index [3]